ABSTRACT Somatic symptom disorder (SSD) is a debilitating disorder that significantly diminishes quality of life and causes psychological distress such as anxiety and depression. The paper explored the efficiency of the eye movement desensitization and reprocessing (EMDR) therapy in SSD. The current investigation is a clinical trial investigating the effectiveness of eye movement desensitization (EMDR) therapy in the treatment of 31 first-diagnosed SSD patients in comparison to age, education and marital status matched 31-first-diagnosed SSD patients who received duloxetine over a 6-week course of treatment. Somatization subscale of the Symptom Checklist-Revised 90 (SCL-90), Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI), and Short Form Health Survey (SF-36) were administered to the participants. EMDR group showed enhanced improvement relative to baseline after 6 weeks of treatment compared to duloxetine group. We concluded that EMDR appears to be a highly promising therapy and should be considered among the first-line interventions in the treatment of SSD.
INTRODUCTION
In the fifth revision of the Diagnostic and Statistical Manual of Mental Disorders, somatoform disorders section was removed and a new section of somatic symptom and related disorders capturing somatic symptom disorder, illness anxiety disorder, conversion disorder, factitious disorder, and psychological factors affecting other medical conditions was defined (Rief & Martin, 2014; Voigt et al., 2012) . The definition of somatic symptom disorder stipulates six months of at least one distressing or disruptive somatic symptom that causes disproportionate and persistent thoughts or anxiety or that takes up excessive time and energy for a principal diagnosis. Even though not clearly known, the prevalence of somatic symptom disorder in general adult population is expected to be around 5% -7% (American Psychiatric Association, 2013) . 
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Given that no single treatment has proven outperform another treatment for a single subtype of somatic symptom disorders, it has been suggested that the selection and intensity of the intervention should be drawn from the severity and complexity of the disorder (Schroder et al., 2012) . Three groups of antidepressants are particularly considered in pharmacological interventions relevant to somatic disorders. These antidepressants are tricyclic antidepressants (TCAs; e.g., amitriptyline, desimipramine, trimipramine, doxepine, opipramol), selective serotonin reuptake inhibitors (SSRIs; e.g., citalopram, escitalopram, sertraline, paroxetine, fluvoxamine or fluoxetine), and selective serotonin and norepinephrine reuptake inhibitors (SNRIs; e.g. venlafaxine, duloxetine) (Kleinstauber et al., 2015) . Systematic reviews of treatment interventions in somatic disorders have consistently concluded that nonpharmacological approaches such as psychotherapy appear to be more effective than pharmacological treatments (Hauser, Bernardy, Arnold, Offenbacher, & Schiltenwolf, 2009; Henningsen, Zipfel, & Herzog, 2007; Wulsin, 2014) .
Recent conceptualizations of pain place importance on the processes taking place in the brain, i.e. cortical reorganization, cognitive and motivation factors (Flor, 2002; Flor, Denke, Schaefer, & Grusser, 2001; Karl, Muhlnickel, Kurth, & Flor, 2004; Price, 2000; Turk, 2003) . Of note is the fact that affective component of the noniceptive sensations has not been sufficiently taken into account in the previous models of chronic pain (Ray & Zbik, 2001) . More recent models hold the premise that the role of the emotion is central in the genesis and maintenance of chronic pain and in turn suggest that treatment should be tailored in a manner addressing the emotional component of noniceptive sensations (Price, 2000; Rome & Rome, 2000; Schneider, Hofmann, Rost, & Shapiro, 2007; van Rood & de Roos, 2009) .
Eye movement desensitization and reprocessing (EMDR) is built on the adaptive information processing (AIP) model, which posits that prior affect-laden traumatic experiences result in various patterns of symptoms such as flashbacks, physical sensations and chronic pain (Shapiro, 2001) . In accordance with the extant literature of pain (Ray & Zbik, 2001; Rome & Rome, 2000) , the AIP model prospects that particularly chronic pain is related to past traumatic experiences, which is assumed to be limbically augmented during the sensitization process (Shapiro, 2014) . More importantly, in review of the literature strong evidence with respect to the utilization of EMDR in the treatment of chronic pain has been emerged (Bergmann, 1998; Grant, 1998; Grant & Threlfo, 2002; Schneider et al., 2007; Schneider, Hofmann, Rost, & Shapiro, 2008) .
The focus of the current study was to compare the effectiveness of EMDR and duloxetine in the treatment of patients with somatic symptom disorder. It was hypothesized that painful memories are the antecedents of limbically augmented somatic symptomatology, in which EMDR can be used to reprocess and change somatic reactions to emotionally charged memories linked to somatization.
METHOD Participants
The trial involved 62 first-time-diagnosed patients with somatic symptom disorder (SSD) consecutively admitted to the psychiatry clinics of Yüzüncü Yıl University Training and Education Hospital and Bağcılar Training and Education Hospital due to the medically unexplained physical symptoms.
Patients were included into the study after being thoroughly informed about the research protocol and providing written informed consent for participation. Inclusion criteria were voluntary agreement of participation, first-time diagnosis based on DSM-5 criteria for SSD, age 18> and 65< years, and no history of other psychiatric problems.
Participants were randomized utilizing the SCL-90 somatization subscale score of each patient with SSD determined at baseline, before commencement of the trial, to one of 2 treatment modalities: 1) EMDR alone or 2) duloxetine alone, so as to minimize group difference in mean somatization score. The study required nearly 1 year to complete since the aim of the study was to recruit only patients diagnosed for the first time with SSD who had not received any psychotherapy or pharmacotherapy before.
The study was conducted according to the Declaration of Helsinki. All investigative procedures were reviewed and approved by the Institutional Ethics Committee of the Yüzüncü Yıl University, Faculty of Medicine. All participants signed a consent form declaring that they had been fully informed about the purposes, procedures, and conduct of the study. The volunteers were not compensated for their participation.
Treatment Protocols
Half of the women patients (n=31) with SSD received duloxetine treatment alone and no other therapies were provided during the study period. The other half of the sample matched for age, marital status and education was treated with EMDR alone and no other therapies or pharmacotherapy was provided to EMDR group.
Duloxetine, a serotonin norepinephrine reuptake inhibitor (SNRI), was started at a dose of 30 mg/day, always in the morning, for the first week of the trial and thereafter, from the second week of the trial provided at a dose of 60 mg/day.
EMDR treatment consisted of 6 weekly sessions lasting 90 minutes. The EMDR sessions were tailored according to the treatment guidelines for somatic symptomatology (Luber, 2009; Schneider et al., 2007) that were adapted from the basic EMDR protocol developed by Shapiro (2001) . During the EMDR sessions although eight step standard protocol was followed by the therapists, somatic sensations and relevant painful memories became the focus of the therapeutic intervention. The antecedents of somatic sensations and affective components of the physical symptoms were targeted and reprocessed during the EMDR sessions.
Outcome variables
A battery of self-report instruments evaluating health well-being, somatization, depression and anxiety levels was administered at the beginning and at the end of the treatment. Self-report measures included the following.
Somatization subscale of the Symptom Checklist-90-Revised (SCL-90-R)
The SCL-90 R (Derogatis, 1977 ) is a brief self-report questionnaire developed to assess a broad range of psychological symptoms of psychopathology. The questionnaire is also used in measuring improvement in symptoms as outcomes of pharmacological and psychotherapy treatments. We used only somatization subscale of the SCL-90 R in the present study. The somatization subscale consists of 12 items. The Turkish validation of the psychometric instrument was conducted by Kılıç (1991) .
Beck Anxiety Inventory (BAI)
The BDI (Beck, Brown, Epstein, & Steer, 1988 ) was developed to assess frequency and intensity of physiological symptoms of anxiety. The instrument consists of 21 items, each rated on a four-point scale from 0 to 3. The BAI yields a total score ranging from 0 to 63, with higher scores indicating more severe anxiety symptoms. The Turkish version of the BAI was demonstrated to have good reliability and validity (Ulusoy, Sahin, & Erkmen, 1998 ).
Beck Depression Inventory (BDI)
The BDI (Beck, Rush, Shaw, & Emery, 1979 ) is designed to assesses frequency and intensity of depressive symptoms. The instrument consists of 21 items, each rated on a four-point scale from 0 to 3. The BDI yields a total score ranging from 0 to 63, with higher scores indicating more severe depressive symptoms. The Turkish version of the instrument had adequate reliability and validity (Hisli, 1989 ).
Short Form Health Survey (SF-36)
The SF-36 (Ware & Sherbourne, 1992 ) is one of the most widely used screening tool developed to assess health status and quality of life. The instrument consists of 36 items that yield ten domains. Physical Functioning assesses problems with physical activities. The RolePhysical and Role-Emotional domains measure debilitation at work or other daily activities as a result of physical health or emotional problems. Bodily Pain assesses limitations due to pain, and Vitality measures energy and tiredness. The Social Function domain evaluates functioning relevant to physical and emotional health on normal social activities, and Mental Health assesses psychological wellness. The General Health domain evaluates perception and expectation of personal health. These subscales are assumed to form two distinct higherorder clusters of Physical and Mental Components. All domains are scored on a scale from 0 to 100 and the scores are standardized with a mean of 50 and a standard deviation of 10. Three subscales (Physical Function, Physical Role, and Bodily Pain) contribute to the scoring of the Physical Component Summary Measure and three subscales of mental functioning (Role-Emotion, Social Function, and Mental Health) contribute to the scoring of the Mental Component Summary Measure. The Turkish translation of the SF-36 was conducted by Demiral et al. (2006) .
Statistical Analysis
Descriptive statistics were derived for demographic variables and sample characteristics were compared between EMDR and duloxetine treatments groups using F test and χ 2 test statistics. The mean scale scores of the 2 treatment groups measured at pre-and post-treatment periods were compared using one-way analysis of variance. Repeated-measures analysis of variance (rANOVA) models were run to evaluate change on psychometric instrument scores obtained over 6 weeks of the treatment. The threshold for statistical significance was P<0.05.
RESULTS
All 62 women patients with SSD completed the trial; 31 patients received duloxetine alone and 31 patients received EMDR without pharmacotherapy. The mean age of the overall sample (62 patients) was 28.02 (SD ± 6.32) years, ranging from 18 to 39. Some 53.23% of the participants were married, and 38.71% had college education. As shown in Table 1 , the mean age, level of education and marital status did not differ according to the treatment group (ANOVA and χ 2 tests). Table 2 and 3 report the mean baseline and followup scale scores of the 2 treatment groups. The mean scale scores were comparable between 2 treatment groups at the beginning of the treatment, with an exception of that the mean baseline BAI score was statistically significantly greater in the EMDR therapy group than duloxetine group.
The mean scale scores of the somatization subscale of the SCL-90 R, BAI, BDI, and components of the SF-36 of both treatment groups significantly declined during the 6-week protocol. The mean somatization scale score of EMDR group was better reduced from baseline than duloxetine alone group. More importantly, it was the case for the BDI, BAI, and subscales of the SF-36. Accordingly, over the 6-week course of therapy, reduction of the mean scale scores was indicative of the enhanced therapeutic effect of EMDR observed at the end of the trial, in comparison to duloxetine treated patients. Findings are presented in Table 2 and 3. 
DISCUSSION
The therapeutic response to antidepressant medications is often delayed up to 4-6 weeks (Stahl, 2013) . A meta-analysis of 27 studies, consisting of a total of 1781 participants who has received short-term psychotherapy for multiple medically unexplained physical symptoms identified small to large within-group effect sizes for repeated assessments for the different outcome variables. Researchers concluded that psychotherapy seem to play an important role in the treatment of physical symptoms relative to pharmacotherapy that facilitate passivity of patients, support somatic health beliefs and convey the risk of side effects (Kleinstauber, Witthoft, & Hiller, 2011) . Thus, strategies to improve the strength and extent of the therapeutic outcomes in somatic disorders are the major clinical interest. The current study explored whether an enhanced and a more rapid therapeutic effect is obtained in women SSD patients when EMDR was administered over a six-week course of the treatment than when duloxetine antidepressant pharmacotherapy is administered alone in the morning. The results of the current follow-up study showed that SSD patients who received EMDR therapy versus those patients with SSD who received duloxetine alone experienced significantly sheerer reduction of not only somatization as measured on the respective subscale of the SCL-90, but also the BDI, BAI, and the SF-36 outcome measures, including all subscales of the SF-36. Moreover, any adverse effects of EMDR such as prolonged sleep terrors or inflated anxiety were not reported by the patients.
In a systematic review of the relevant literature, Shapiro (2014) places emphasize on the beneficial implications of EMDR in that many patients suffering from somatization and chronic pain who may actually debilitated by unprocessed painful memories encoded along with the somatic sensations. The adaptive Information Process (AIP) model holds that chronic pain is assumed to involve the automatic emotional reactions in response to the sensations elicited by nociceptive receptors. Pain reactions also may be stimulated by physiologically stored memories of similar sensations, which is suggested to contain images and thoughts as well as physical sensations. Adverse memories may convey affective aspects of traumatic experiences that are probably out of conscious awareness and are significantly associated with pain or somatization. The prospect of the AIP model includes EMDR therapy can result in completely elimination of the stressful somatic perception. The previous studies of EMDR have provided robust evidence empirically supporting the theoretical considerations of the AIP model that EMDR therapy for phantom limb pain which is assumed to be caused by the unprocessed painful memories containing the physical sensations during the time of the event indicate an excessive success rate as defined by almost complete elimination of the painful somatic sensations (de Roos et al., 2010; Russell, 2008; Schneider et al., 2008; Wilensky, 2006) . Completed processing of the memory through is premised to include an integration and reconsolidation of the originally stored memory that results in alterations in emotions, beliefs and bodily sensations (Shapiro, 2001 (Shapiro, , 2007 Solomon & Shapiro, 2008) . Therefore, EMDR therapy is beneficial in the treatment of chronic pain and somatic symptoms. Consistent with accumulated evidence in the literature supporting the potent efficacy of EMDR in the treatment of somatic symptoms (Kleinstauber et al., 2011; Tefft & Jordan, 2016; Tesarz et al., 2014 ) the present results provided further support and extended the relevant findings. The reported scores of EMDR treated patients with SSD on the SF-36 improved considerably in all domains. Enhanced therapeutic outcomes were also evident for highly reduced scores of somatization subscale of the SCL-90 R, depression and anxiety over 6 week course of the EMDR treatment that can be attributable to the validity of basic hypothesis of the AIP model as to the significant associations between emotions and somatic sensations on the basis of prior painful memories (Shapiro, 2001 (Shapiro, , 2014 . More importantly, in consonant with previous suggestions as to effectiveness of psychotherapy in the literature (Hauser et al., 2009; Henningsen et al., 2007; Wulsin, 2014 ) the greater effect sizes in EMDR alone treated group relative to duloxetine treatment which were indicative of incomparable improvement in outcome measures showed that EMDR therapy should be considered as one of the first-line treatment alternatives in SSD. This study has several limitations one should bear in mind while interpreting these findings. First, the sample sizes were relatively small in both EMDR and duloxetine groups. Second, although the study was conducted with a longitudinal research design including pre-and posttreatment measurements of the therapeutic outcomes, a follow-up measurement could have significantly contributed to the assessment of the long-term stability of improvements of EMDR therapy on outcome measures. Third, a combination of EMDR therapy plus duloxetine treatment group could have been helpful to more reliably evaluate the effectiveness of EMDR therapy relative to pharmacotherapy in SSD. In the treatment guidelines of somatic-related disorders and pain, cognitive-behavior therapy (CBT) have been recognized as one of the most widely accepted first-line nonpharmacological intervention indeed (e.g. Wulsin, 2014) . Efficacy of EMDR therapy versus CBT should be investigated in further case controlled randomized trials including an additional pharmacotherapy alone or combination treatment group. Finally, the current sample of patients in both treatment groups consisted of women patients with first-timediagnosis patients with SSD. Effectiveness of EMDR therapy should be warranted in male patients suffering from SSD.
Both treatment groups revealed significant decreases in somatization levels as rated on the respective subscale of the SCL-90 and somatization-related physical and mental health function reported on the SF-36 subscales. Either duloxetine or EMDR treatment resulted in substantial decrease in both anxiety and depression scores as well. However, EMDR treatment exhibited excess of the effect sizes relative to SNRI group.
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